Bad players in AL amyloidosis in the current era of treatment
Key result
Recent advancements in echocardiography, cardiac MRI, and new biological markers show promise for improving risk assessment and prognostic models in systemic AL amyloidosis.
Why the study?
Existing prognostic models for systemic AL amyloidosis rely on cardiac biomarkers with low specificity and dependence on confounders, while new therapies and advancing imaging and biological markers are emerging.
Design
Literature review
Authors
Discussion
Loading...
Member takes
Implication
New imaging and biomarkers may refine AL amyloidosis risk assessment; leaves open prospective multicenter validation before adoption.
Structured PICO
P
Population
Patients with systemic AL amyloidosis
I
Intervention
Prognostic assessment using cardiac biomarkers, echocardiography (ECHO), cardiac MRI (CMR), and new biological markers
O
Outcome
Prognosis and risk assessment
This review emphasizes the evolving landscape of prognostic markers in AL amyloidosis, highlighting the roles of advanced imaging and novel biomarkers in refining risk assessment.
Cite This Study
Kreiniz et al. (2023) conducted a review in Systemic AL amyloidosis (ALA). Recent advancements in echocardiography, cardiac MRI, and new biological markers show promise for improving risk assessment and prognostic models in systemic AL amyloidosis.